• Gastrointestinal neuroendocrine carcinomas
• Gastrointestinal neuroendocrine neoplasms
• Mixed gastrointestinal neuroendocrine neoplasms
• Neuroendocrine carcinoma
• Neuroendocrine neoplasms
• Neuroendocrine non-neuroendocrine neoplasms

The prevalence of gastrointestinal neuroendocrine tumors (GI-NETs) is increasing, and despite recent advances in their therapy, it remains inadequate in patients with advanced well-differentiated neuroendocrine tumors. These tumors present many challenges concerning the molecular basis and genomic profile, pathophysiology, clinicopathological features, histopathologic classification, diagnosis and treatment. There has been an ongoing debate on diagnostic criteria and clinical behavior, and various changes have been made over the last few years. Neuroendocrine carcinoma of the gastrointestinal system is a rare but highly malignant neoplasm that is genetically distinct from gastrointestinal system neuroendocrine tumors (NETs). The diagnosis and management have changed over the past decade. Emerging novel biomarkers and metabolic players in cancer cells are useful and promising new diagnostic tools. Progress in positron emission tomography-computerized tomography and scintigraphy with new radioactive agents (⁶⁴Cu-DOTATATE or ⁶⁸Ga-DOTATATE) replacing enough octreoscan, has improved further the current diagnostic imaging. Promising results provide targeted therapies with biological agents, new drugs, chemotherapy and immunotherapy. However, the role of surgery is important, since it is the cornerstone of management. Simultaneous resection of small bowel NETs with synchronous liver metastases is a surgical challenge. Endoscopy offers novel options not only for diagnosis but also for interventional management. The therapeutic option should be individualized based on current multidisciplinary information.

• Gastrointestinal neuroendocrine tumors
• Neuroendocrine neoplasms
• Mixed NEN
• Neuroendocrine carcinoma
• APUD cells
• Carcinoids
• Somatostatin analogs